Next-generation immunotherapy to fight resistant bacterial infections

According to the World Health Organization, bacterial infections are responsible for around 20% of global deaths. 
NanoBiCar aims to develop a novel immunotherapeutic strategy to combat these infections, using tuberculosis (TB) as a proof of concept. 

Current antibiotic-based treatments are limited by antimicrobial resistance and poor efficacy against intracellular pathogens. NanoBiCar will explore three innovative mRNA-based platforms, delivered via lipid nanoparticles, to eliminate both intra- and extracellular bacteria. These therapies, not previously applied to bacterial diseases, are safe, specific, affordable, and effective regardless of host immune status or bacterial resistance—ideal for high-burden, low-resource settings.